



Press Release

Novel Flu Vaccine: CILIAN and PROINNOVERA collaborate in clinical development

Both companies are working to resolve manufacturing challenges associated with flu vaccines

Muenster, Germany, 29 October 2012:

PROINNOVERA GmbH and CILIAN AG will jointly advance the clinical development of CiFlu[®], a novel, recombinant human vaccine against flu developed by CILIAN. The two companies, both based in Muenster, Germany, are already collaborating to reach an important milestone for regulatory approval and initiation of clinical development, the Scientific Advice. Clinical studies are scheduled to begin in 2013. With this novel concept of a recombinant flu vaccine, both companies attempt to offer a medium-term solution for the currently experienced supply issues with seasonal and pandemic flu vaccines.

CiFlu[®] is a novel, biotechnologically manufactured subunit vaccine against flu. It employs CILIAN's proprietary production technology based on ciliates as expression organism. In contrast to traditional methods of production for flu vaccines, based for example on culture of whole viruses in eggs or in tumor cells of dogs, CILIAN's method produces only surface proteins of flu viruses. These subunit vaccines, compared to conventional vaccines, possess a much higher purity. As a result, the vaccine is safer, better tolerated, can be manufactured without use of antibiotics and, at the same time, shortening production time significantly. CiFlu[®] can help to avoid shortages of supply such as those repeatedly experienced recently with conventional flu vaccines. It can also ensure that sufficient quantities are available on time for the start of a flu season.

About Proinnovera GmbH

PROINNOVERA GMBH is a CRO for clinical research and development of pharmaceuticals. The company is offering clinical contract development for innovative pharmaceuticals to pharmaceutical companies within the frame of precise development planning and the corresponding implementation. PROINNOVERA is conducting clinical studies since 1997 from early phases up to market entry. Further more PROINNOVERA offers consultation for emerging biotech companies within the scope of scientific collaborations for the analysis and optimisation of new drug development projects.

About Cilian AG

CILIAN AG is a young, dynamic biotechnology company that is engaged in the development and application of an innovative expression system for the pharmaceutical industry. CILIAN AG uses eukaryotic, single cell microorganisms, called ciliates, as its production organisms. Specifically, ciliates are currently employed in the development and production of vaccines; monoclonal antibodies; and other therapeutic proteins.

For further information please visit our webpage at: www.cilian.com and www.proinnovera-cro.de/en or contact us at:

Cilian AG:

Dr. Marcus Hartmann, CSO
Tel. +49 251 6 20 310
hartmann@cilian.de

Proinnovera GmbH:

Dr. Burkhard Breuer, CEO
Tel. +49 251 270 778 0
breuer@proinnovera-cro.de